P032

Thomas P. Leist | thomas.leist@jefferson.edu

Prognostic Value of On-Treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People With Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials

Thomas P. Leist[1], Stephen L. Hauser[2], Tobias Derfuss[3], Heinz Wiendl[4], Douglas L. Arnold[5], Xavier Montalban[6], Alit Bhatt[7], Wenjia Wei[8], Ibolya Boer[8], Enrique Alvarez[9], Tjalf Ziemssen[10]

[1]Thomas Jefferson University, Philadelphia, PA, USA; [2]UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA; [3]Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland; [4]Institute of Translational Neurology, University of Münster, Münster, Germany; [5]Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada; [6]Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain; [7]Novartis Healthcare Pvt. Ltd., Hyderabad, India; [8]Novartis Pharma AG, Basel, Switzerland; [9]Rocky Mountain MS Center, University of Colorado School of Medicine, Aurora, CO, USA; [10]Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany

Scan to access full poster

To download a copy of this poster, visit the web at: https://bit.ly/actrims-forum

KEY FINDINGS & CONCLUSIONS

- On-treatment sNfL levels at 3 and 12 months are prognostic for future lesion formation and support the use of a single sNfL threshold to prognosticate MS disease activity in pwRMS on DMT

Please refer to these related posters for more details on the prognostic value of sNfL:

- Baseline Serum Neurofilament Light Chain Levels Predict Future Disease Activity Irrespective of Race/Ethnicity: Results From the Phase 3 ASCLEPIOS I/II Trials (**P036**)
- Prognostic Value of Serum Neurofilament Light Chain for Disease Activity in Patients With Relapsing Multiple Sclerosis: Results From Subgroup Analysis Based on Body Mass Index and Age From the Phase 3 ASCLEPIOS I/II Trials (**P037**)

This study was sponsored by Novartis Pharma AG, Basel, Switzerland.

Poster presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, February 29–March 2, 2024.

INTRODUCTION

- A challenge encountered in clinical practice with relapsing multiple sclerosis (RMS) is the difficulty in prognosticating the risk of future disease activity because of the variable disease course across patients[1]
- Inflammatory disease activity mostly occurs in the younger RMS population and declines with age[2]
  - A biomarker that can prognosticate disease activity may help optimize individualized patient care and limit irreversible neurological damage, even in the absence of overt clinical symptoms or radiological signs[3]
- In the phase 3 ASCLEPIOS I/II trials (ofatumumab vs teriflunomide in people with RMS [pwRMS]), a pre-planned analysis of baseline serum neurofilament light chain (sNfL) levels based on being above or below the baseline median, found that sNfL levels were prognostic for on-study lesion formation and brain volume loss in the overall population and in recently diagnosed treatment-naive participants[4]
- The prognostic value of sNfL was also observed when participants were categorized by baseline sNfL concentration quartiles[5]
  - Irrespective of treatment, participants in the lowest quartile (Q1) had the lowest risk for on-study new or enlarging [ne] T2 lesions, with the risk for neT2 lesions increasing sequentially up to the highest sNfL quartile (Q4)

OBJECTIVE

- To evaluate the prognostic value of 3- and 12-month on-treatment sNfL levels for future disease activity in pwRMS

METHODS

Study design

- ASCLEPIOS I/II were two phase 3, double-blind, active-controlled trials in which participants with RMS were randomized to receive either ofatumumab or teriflunomide for up to 30 months
- Participants aged 18–55 years with a diagnosis of RMS, Expanded Disability Status Scale (EDSS) score 0–5.5, ≥1 relapse in the year before screening or ≥2 relapses in the last 2 years before screening, or ≥1 gadolinium-enhancing (Gd+) lesion on magnetic resonance imaging (MRI) in the year before randomization were included
- Due to the event-driven design, participants were switched to open-label ofatumumab following a variable duration in the core study:
  - The first switches to open-label treatment occurred during Year 1, and all participants were switched by the end of Year 3
  - The median time in the core study was 1.6 years (1.5 years in ASCLEPIOS I and 1.6 years in ASCLEPIOS II), and >30% of the participants had time in trial longer than 2 years
- The baseline sNfL cutoff was predefined in the clinical study protocol (i.e., before measuring sNfL or any clinical or radiological outcomes), as the median sNfL value for the overall population across ASCLEPIOS I/II (9.3 pg/mL)
- Participants were stratified into high (≥9.3 pg/mL) and low (<9.3 pg/mL) sNfL groups based on this median baseline sNfL concentration

Assessments

- Quantification of sNfL levels was performed centrally (Navigate BioPharma Services, Carlsbad, CA, USA), as a single batch at the end of the trials, using a validated Quanterix Simoa® NF-light advantage kit
- MRI scans were performed at baseline, Months 12 and 24, and end of treatment/end of study
- The prognostic value of high versus low sNfL at Months 3 and 12 was analyzed for the annualized rate of neT2 lesions

Statistical analysis

- The number of neT2 lesions on the last available scan relative to the Month 12 scan was analyzed in a negative binomial regression model adjusting for sNfL category at the respective month, with time (in years) between the two scans as an offset

RESULTS

Participant characteristics

- Of the 1882 participants randomized in the ASCLEPIOS I/II trials, 1746 had baseline sNfL data. Of these 1746 participants, 1393 and 1384 had neT2 and sNfL data at Months 3 and 12, respectively
- Baseline demographic and disease characteristics by sNfL category (low vs high) at Months 3 and 12 were similar between sNfL groups, except the mean number of Gd+ lesions and T2 lesion volume, which were considerably higher in participants with high sNfL versus low sNfL (**Table 1**)

Table 1. Baseline demographic and disease characteristics for participants stratified by sNfL category at Months 3 and 12

Characteristic	Month 3		Month 12	
	Low sNfL (<9.3 pg/mL) N=951[a]	High sNfL (≥9.3 pg/mL) N=758[a]	Low sNfL (<9.3 pg/mL) N=1059[a]	High sNfL (≥9.3 pg/mL) N=559[a]
Age, years	38.3±8.6	38.2±9.8	37.1±8.7	40.3±9.4
Female, n (%)	647 (68.0)	515 (67.9)	734 (69.3)	373 (66.7)
BMI, kg/m^2	26.8±6.5	24.7±5.3	26.2±6.1	24.9±5.4
MS duration since first symptom, years	8.0±7.2	8.2±7.1	7.4±6.7	9.4±7.6
Previously treated with DMT, n (%)	545 (57.3)	471 (62.1)	596 (56.3)	359 (64.2)
Number of relapses in the year before the study	1.2±0.7	1.3±0.7	1.2±0.7	1.3±0.7
Time since onset of most recent relapse, months	7.8±13.5	6.9±9.1	7.5±13.2	7.3±9.2
EDSS score	2.8±1.3	3.0±1.4	2.7±1.3	3.2±1.4
Normalized brain volume, cm^3	1446.5±75.2	1437.2±81.5	1449.6±74.3	1427.2±80.7
Number of Gd+ T1 lesions	0.5±1.4	2.7±5.5	1.3±3.8	1.9±4.6
Participants free of Gd+ T1 lesions, n (%)	703 (73.9)	342 (45.1)	678 (64.0)	311 (55.6)
T2 lesion volume, cm^3	10.1±11.4	16.7±15.1	11.1±11.9	16.7±15.4
Median sNfL, pg/mL	7.15	13.96	7.98	12.17

[a]Only participants with non-missing sNfL values at Month 3/Month 12 are included. Data are expressed as mean±standard deviation unless specified otherwise.
BMI, body mass index; DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; Gd+, gadolinium-enhancing; MS, multiple sclerosis; sNfL, serum neurofilament light chain.

Prognostic value of on-treatment sNfL for neT2 lesions

- The mean annualized rate of neT2 lesions was significantly higher in participants with high sNfL versus low sNfL at Months 3 and 12
  - neT2 lesions were 2.2-fold in participants with high sNfL at Month 3 compared with those with low sNfL (116.6% increase, p<0.001; **Figure 1**)
  - Likewise, neT2 lesions were 3.6-fold in participants with high sNfL at Month 12 compared with those with low sNfL (257.0% increase, p<0.001; **Figure 1**)

Figure 1. Mean annualized rate of neT2 lesions in participants per sNfL level at Months 3 and 12[a]



[a]Analyses were based on the population that had both baseline sNfL and neT2 data available.
neT2, new or enlarging T2 lesion; sNfL, serum neurofilament light chain.

LIMITATIONS

- Based on the pre-planned nature of the analysis, participants were stratified by baseline median sNfL value into "high" or "low" with the intention to divide a typical phase 3 trial RMS population into groups of equal size with higher versus lower than median sNfL
- The results reported here are based on the protocol-defined single sNfL threshold; future work should evaluate how this single sNfL threshold could be optimized, with a specific target and population in mind
- The use of a single NfL threshold may be applicable mainly to relatively young RMS populations (18–55 years) such as the population included in these trials, which is the population for which prognostication of disease activity is most relevant
- The data presented in this study are based on a population that was selected according to the ASCLEPIOS inclusion/exclusion criteria, and although they represent a typical population suitable for phase 3 trials/regulatory purposes, they may not reflect the broader population of individuals with RMS seen in everyday clinical practice
  - The population enrolled in the ASCLEPIOS I/II trials may not reflect older RMS "community-based" populations, who may have comorbidities that may impact NfL levels (e.g., diabetes, neurodegenerative disorders)

References

1. Oh J, et al. *Curr Opin Neurol.* 2018;31:752–759.
2. Dahlke F, et al. *Mult Scler.* 2021;27:2062–2076.
3. Thebault S, et al. *Mult Scler.* 2022;28:1491–1497.
4. Ziemssen T, et al. *Front Immunol.* 2022;13:852563.
5. Hauser SL, et al. *N Engl J Med.* 2020;383:546–557.

Abbreviations

BMI, body mass index; **DMT,** disease-modifying therapy; **EDSS,** Expanded Disability Status Scale; **Gd+,** gadolinium-enhancing; **MRI,** magnetic resonance imaging; **MS,** multiple sclerosis; **neT2,** new or enlarging T2 lesions; **pwRMS,** people with relapsing multiple sclerosis; **RMS,** relapsing multiple sclerosis; **sNfL,** serum neurofilament light chain.

Disclosures

Thomas P. Leist serves as site investigator for Biogen, BMS, EMD Serono, Genentech/Roche, Janssen, Novartis, and Sanofi. He has advised Biogen, Genentech/Roche, Horizon, Janssen, and Novartis. **Stephen L. Hauser** currently serves on the scientific advisory board of Accure, Alector, Annexon. He has previously consulted for BD, Moderna, NGM Bio, Pheno Therapeutics and previously served on the Board of Directors of Neurona. Dr. Hauser also has received travel reimbursement and writing support from F. Hoffmann-La Roche and Novartis AG for anti-CD20 therapy–related meetings and presentations. Grants: NIH/NINDS (R35NS111644), NMSS (SI-2001-35701), and Valhalla Foundation. **Tobias Derfuss** received speaker fees, research support and travel support from, and/or served on advisory boards or steering committees for Alexion, Novartis Pharma, Merck Serono, Biogen, GeNeuro, Roche, and Genzyme. **Heinz Wiendl** declares that he has acted as a member of the Scientific Advisory Boards of Alexion, Argenx, Biocryst, BMS, Cellerys, Galapagos, Janssen, Merck, Novartis, Sandoz-Hexal, and Uniqure. He also declares that he has received speaker honoraria and travel support from Alexion, Biogen, BMS, EPG Health, Genzyme, Merck, Neurodiem, Novartis, Ology, Roche, Teva and WebMD Global and acts as a paid consultant for AbbVie, Actelion, Argenx, Biogen, BMS, EMD Serono. He is acting as a paid consultant for Actelion, Argenx, BD, BMS, Dianthus, EMD Serono, EPG Health, Fondazione Cariplo, Gossamer Bio, Idorsia, Immunic, Immunovant, Immune Bio, Syneos Health, Janssen, LTS, Merck, NexGen, Novartis, Roche, Samsung, Sangamo, Sanofi, Swiss Multiple Sclerosis Society, Teleranzia, UCB, Viatris, VirBio, and Worldwide Clinical Trials. His research is funded by Alexion, Amicus Therapeutics, Argenx, Biogen, CSL Behring, F. Hoffmann-La Roche, Genzyme, Merck, Novartis, Roche, and UCB. **Douglas L. Arnold** reports personal fees from Biogen, Biohaven, BMS, Eli Lilly, EMD Serono, Find Therapeutics, Frequency Therapeutics, Gossamer Bio, GSK, Kiniksa, Merck, Novartis, Sanofi, Shionoggi, outside the submitted work; and ownership interest in NeuroRx. **Xavier Montalban** has received speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with AbbVie, Actelion, Alexion, Biogen, BMS/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, MedDay, Merck, Mylan, NervGen, Novartis, Sandoz, Sanofi-Genzyme, Teva, TG Therapeutics, EXCEMED, MSIF, and NMSS. **Enrique Alvarez** received compensation for consulting from Alexion, Biogen, Celgene/BMS, EMD Serono/Merck, Genentech/Roche, Horizon/Amgen, Motric Bio, Novartis, Sanofi, Scionic, and TG Therapeutics, and for research from Atara, Biogen, Genentech/Roche, Novartis, Sanofi, TG Therapeutics, Patient-Centered Outcomes Research Initiative, National Multiple Sclerosis Society, National Institutes of Health, and Rocky Mountain MS Center. **Tjalf Ziemssen** has received personal compensation for participating in advisory boards, trial steering committees, and data and safety monitoring committees, as well as for scientific talks and project support from Almirall, Bayer, BAT, Biogen, Celgene, Sanofi Genzyme, Merck, Novartis, Roche, Vitaccess, and Teva. **Alit Bhatt, Wenjia Wei,** and **Ibolya Boer** are employees of Novartis.

Acknowledgments

Medical writing support was provided by Lakshmi Narendra Bodduluru and Paul Coyle (employees of Novartis Healthcare Pvt. Ltd., Hyderabad, India, and Novartis Ireland Ltd., Dublin, Ireland, respectively) and design support by Hari Prasad (employee of Novartis Healthcare Pvt. Ltd., Hyderabad, India).